Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Walter

Showing results (321-330 of 334) with videos related to

Pageof 34
Sort By:
Nature Communications|March 4, 2025
Comprehensive molecular portrait reveals genetic diversity and distinct molecular subtypes of small intestinal neuroendocrine tumorsCéline Patte, Roxane M Pommier, Anthony Ferrari, et al.
The Lancet. Oncology|June 1, 2026
[<sup>177</sup>Lu]Lu-dota-tate versus sunitinib in patients with metastatic progressive neuroendocrine tumours of the pancreas (OCLURANDOM): a randomised, controlled, phase 2 trialEric Baudin, Alice Durand, Amandine Beron, et al.
Cancer Discovery|September 13, 2024
TREM2-Expressing Multinucleated Giant Macrophages Are a Biomarker of Good Prognosis in Head and Neck Squamous Cell CarcinomaGrégoire Gessain, Ahmed-Amine Anzali, Marvin Lerousseau, et al.
Lancet (London, England)|July 2, 2026
[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trialThomas Walter, Henning Jann, Catherine Ansquer, et al.
Frontiers in Pharmacology|July 10, 2025
KU124 (9,10,10-trioxo-N-(2-phenylphenyl)thioxanthene-3-carboxamide) as a novel inhibitor of TASK-1Ana Dumani, Annette Jacob, Diego Chavez, et al.
Medical Image Analysis|December 31, 2014
Assessment of algorithms for mitosis detection in breast cancer histopathology imagesMitko Veta, Paul J van Diest, Stefan M Willems, et al.
Endocrine-Related Cancer|March 17, 2023
COVID-19 in patients with neuroendocrine neoplasms: 2-year results of the INTENSIVE studyNicola Fazio, Lorenzo Gervaso, Thorvardur R Halfdanarson, et al.
The Journal of Clinical Endocrinology and Metabolism|January 30, 2024
Beyond MEN1, When to Think About MEN4? Retrospective Study on 5600 Patients in the French Population and Literature ReviewBenjamin Chevalier, Lucie Coppin, Pauline Romanet, et al.
BMC Cancer|April 4, 2025
A Randomized clinical trial evaluating the impact on survival and quality of life of <sup>177</sup>Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)Jaume Capdevila, Virginia Pubul, Urbano Anido, et al.
BMC Cancer|June 13, 2026
Correction: A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)Jaume Capdevila, Virginia Pubul, Urbano Anido, et al.
Pageof 34

Showing results (321-330 of 334) with videos related to

Sort By:
Pageof 34
Nature Communications|March 4, 2025
Comprehensive molecular portrait reveals genetic diversity and distinct molecular subtypes of small intestinal neuroendocrine tumorsCéline Patte, Roxane M Pommier, Anthony Ferrari, et al.
The Lancet. Oncology|June 1, 2026
[<sup>177</sup>Lu]Lu-dota-tate versus sunitinib in patients with metastatic progressive neuroendocrine tumours of the pancreas (OCLURANDOM): a randomised, controlled, phase 2 trialEric Baudin, Alice Durand, Amandine Beron, et al.
Cancer Discovery|September 13, 2024
TREM2-Expressing Multinucleated Giant Macrophages Are a Biomarker of Good Prognosis in Head and Neck Squamous Cell CarcinomaGrégoire Gessain, Ahmed-Amine Anzali, Marvin Lerousseau, et al.
Lancet (London, England)|July 2, 2026
[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trialThomas Walter, Henning Jann, Catherine Ansquer, et al.
Frontiers in Pharmacology|July 10, 2025
KU124 (9,10,10-trioxo-N-(2-phenylphenyl)thioxanthene-3-carboxamide) as a novel inhibitor of TASK-1Ana Dumani, Annette Jacob, Diego Chavez, et al.
Medical Image Analysis|December 31, 2014
Assessment of algorithms for mitosis detection in breast cancer histopathology imagesMitko Veta, Paul J van Diest, Stefan M Willems, et al.
Endocrine-Related Cancer|March 17, 2023
COVID-19 in patients with neuroendocrine neoplasms: 2-year results of the INTENSIVE studyNicola Fazio, Lorenzo Gervaso, Thorvardur R Halfdanarson, et al.
The Journal of Clinical Endocrinology and Metabolism|January 30, 2024
Beyond MEN1, When to Think About MEN4? Retrospective Study on 5600 Patients in the French Population and Literature ReviewBenjamin Chevalier, Lucie Coppin, Pauline Romanet, et al.
BMC Cancer|April 4, 2025
A Randomized clinical trial evaluating the impact on survival and quality of life of <sup>177</sup>Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)Jaume Capdevila, Virginia Pubul, Urbano Anido, et al.
BMC Cancer|June 13, 2026
Correction: A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)Jaume Capdevila, Virginia Pubul, Urbano Anido, et al.
Pageof 34